MétaCan
Menu
Back to cohort
Record W2801447031 · doi:10.1093/sleep/zsy061.620

0621 Measures of Function, Work Productivity, and Quality of Life From a Phase 3 Study of Solriamfetol (JZP-110) in Patients with Narcolepsy

2018· article· en· W2801447031 on OpenAlexaff
Hélène A. Emsellem, Michael J. Thorpy, Gert Jan Lammers, Colin M. Shapiro, Geert Mayer, Giuseppe Plazzi, D Chen, J Li, L P Carter, Robert J. Ryan, Jed Black, Yves Dauvilliers

Bibliographic record

VenueSLEEP · 2018
Typearticle
Languageen
FieldNeuroscience
TopicSleep and Wakefulness Research
Canadian institutionsUniversity of Toronto
Fundersnot available
KeywordsPlaceboTolerabilityMedicineQuality of life (healthcare)Work productivityInternal medicineNarcolepsyPhysical therapyPsychologyAdverse effectPsychiatryModafinilProductivity

Abstract

fetched live from OpenAlex

Solriamfetol is a selective dopamine/norepinephrine reuptake inhibitor with wake-promoting effects. In a phase 3 study, solriamfetol significantly improved wakefulness and decreased excessive sleepiness in adults with narcolepsy. Health-related quality of life (HRQoL) measures were secondary endpoints. Participants with narcolepsy were randomized to solriamfetol 75mg, 150mg, or 300mg, or placebo for 12 weeks. Secondary measures included the Functional Outcomes of Sleep Questionnaire short version (FOSQ-10), Work Productivity and Activity Impairment questionnaire for Specific Health Problems (WPAI:SHP), and 36-Item Short Form Health Survey version 2 (SF-36v2). Least squares mean (standard error) (LS mean [SE]) change from baseline to week 12 was calculated with significance set at P<0.05. Safety and tolerability were also assessed. Baseline demographics were similar across treatment groups. Solriamfetol 300mg significantly improved the FOSQ-10 score (LS mean [SE]: 300mg, 3.01 [0.42]; placebo, 1.56 [0.40]; P<0.05). Solriamfetol significantly reduced percent overall work impairment on the WPAI at 150mg (LS mean [SE]: 150mg, -19.77 [5.04]; placebo, -4.28 [5.00]; P<0.05) and reduced percent activity impairment at 150 and 300mg (LS mean [SE]: 300mg, -21.27 [3.55]; 150mg, -17.84 [3.35]; placebo, -7.79 [3.42]; P<0.05). Significant improvements in SF-36v2 domains were seen for role physical score (LS mean [SE]: 300mg, 6.46 [1.21]; placebo, 2.38 [1.14]; P<0.05), general health (LS mean [SE]: 75mg, 2.42 [0.84]; placebo, -0.20 [0.81]; P<0.05), and vitality score (LS mean [SE]: 300mg, 4.96 [1.19]; 150mg, 5.83 [1.12]; 75mg, 4.68 [1.15]; placebo, 1.04 [1.12]; P<0.05). The most common treatment-emergent adverse events were headache, nausea, decreased appetite, nasopharyngitis, dry mouth, and anxiety. Solriamfetol improved functioning, and HRQoL, at 300mg, particularly on the vitality (all doses) and role physical domains. HRQoL domains such as emotional and social functioning were not affected. Impairment at work was improved at 150mg, whereas activity impairment outside of work was improved at 150 and 300mg. Safety and tolerability were consistent with previous solriamfetol studies. Jazz Pharmaceuticals.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.016

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0050.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.092
GPT teacher head0.329
Teacher spread0.236 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueSLEEPSame topicSleep and Wakefulness ResearchFrench-language works237,207